A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD

NCT06488313

Status	RECRUITING
Phase	Phase 2
Sponsor	Arcturus Therapeutics, Inc.
Enrollment	9 participants

Key Eligibility Criteria

Inclusion (7)

- Willingness and ability to comply with all the protocol requirements, complete all study visits and sign informed consent.
- Males and Females aged e12 years, at Screening.
- Documented clinical diagnosis of OTC deficiency.
- History of symptomatic hyperammonemia or elevated plasma ammonia or glutamine with clinical stability for at least 1 month prior to Screening.
- Medically managed for OTC deficiency and receiving a stable protein-restricted diet, dietary supplements, and/or ammonia scavenger regimen (if applicable) for at least 28 days.

... and 2 more (see full listing online)

Exclusion (20)

- Uncontrolled hypertension.
- Symptoms of infection for at least 7 days prior to dosing.
- Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated.
- History of any OTC gene therapy, or history of liver-derived stem cell therapy in the past 2 years.
- History of any organ transplant.

... and 15 more (see full listing online)

Locations (1 total)

Uncommon Cures, Chevy Chase, Maryland, United States